Regeneron to Acquire 23andMe Out of Bankruptcy for $256 Million

Regeneron is acquiring substantially all of 23andMe's assets, including its personal genome service and total health and research services, for $256 million through a court-supervised bankruptcy sale145.

The acquisition does not include 23andMe’s Lemonaid Health telehealth business, which is being wound down45.

23andMe filed for Chapter 11 bankruptcy protection in March 2025 amid ongoing financial struggles and privacy concerns following a 2023 data breach45.

Regeneron says it will comply with 23andMe’s existing privacy policies and applicable laws to protect customer data5.

The court hearing to approve the transaction is scheduled for June 17, 2025, and the deal is expected to close in the third quarter of 20254.

Regeneron aims to use its experience in genetic sequencing and data management to build on 23andMe’s mission of helping people learn about their DNA and improve health, while advancing Regeneron’s own health and wellness initiatives45.

Sources:

1. https://www.biopharmadive.com/news/regeneron-23andme-acquire-bankruptcy-genetic-testing/748440/

4. https://www.katc.com/business/company-news/biotechnology-company-regeneron-buying-23andme-for-256-million

5. https://www.cbsnews.com/news/regeneron-23andme-bankruptcy-data/